NRx Pharmaceuticals

Company Overview

Snapshot

Founded in October 2014 by Daniel C. Javitt and Jonathan C. Javitt, NRx Pharmaceuticals operates with 11–50 employees. The company has raised a total of $176.18 million across 7 funding rounds. In May 2021, NRx Pharmaceuticals went public on NASDAQ.

Business overview

NRx Pharmaceuticals is a specialized biopharmaceutical company focused on addressing unmet medical needs for severe central nervous system (CNS) conditions, including bipolar depression with suicidality and post-traumatic stress disorder (PTSD). The company's pipeline leverages a proprietary, dual-targeted mechanism of action that modulates NMDA and 5HT2A receptors. NRx Pharmaceuticals operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving patients and providers globally.

Strategic signal

In September 2025, NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, completed the acquisition of Dura Medical, marking an initial step in establishing a network of interventional psychiatry clinics. This strategic move signals NRx Pharmaceuticals' expansion beyond drug development into direct patient care, aiming to integrate its therapeutic solutions within a broader clinical infrastructure and potentially accelerate market adoption for its CNS treatments.

Company Intelligence Q&A

What was a significant recent strategic acquisition by NRx Pharmaceuticals?

In September 2025, NRx Pharmaceuticals' subsidiary, HOPE Therapeutics, completed the acquisition of Dura Medical. This acquisition represents the initial step in building a network of interventional psychiatry clinics.

Did NRx Pharmaceuticals receive any recent FDA designations for its drug candidates?

In September 2025, NRx Pharmaceuticals secured FDA Fast Track designation for its IV Ketamine formulation NRX-100, specifically for the treatment of suicidal depression. This was further expanded in September 2025 for suicidal depression.

What was a key regulatory approval NRx Pharmaceuticals received in September 2025?

In September 2025, NRx Pharmaceuticals received notification of US Food and Drug Administration approval of a suitability petition for the company's proposed strength of preservative-free ketamine.

What was the most recent funding event for NRx Pharmaceuticals?

In August 2024, NRx Pharmaceuticals announced up to $16 million in senior secured debt financing from Anson Funds.

When did NRx Pharmaceuticals go public?

NRx Pharmaceuticals went public on NASDAQ in May 2021.